CUePEAK Bio Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Early Stage VC
- Investors
-
8
CUePEAK Bio General Information
Description
Developer of atopic dermatitis designed for the treatment of skin disease. The company discovers and develops drugs for multiple uses by synthesizing a compound based on Acylhydrazone, enabling patients with treatment for various skin diseases and skin cancer.
Contact Information
Website
www.cuepeakbio.comCorporate Office
- Room 301, 302, Bio Venture Center (BVC)
- Korea Research Institute of Bioscience and Biotechnology, 125, Gwahak-ro, Yuseong-gu
- Daejeon, 34141
- South Korea
Corporate Office
- Room 301, 302, Bio Venture Center (BVC)
- Korea Research Institute of Bioscience and Biotechnology, 125, Gwahak-ro, Yuseong-gu
- Daejeon, 34141
- South Korea
CUePEAK Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Early Stage VC | 20-Feb-2024 | Completed | Generating Revenue | |||
| 4. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 3. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 2. Debt - General | 01-Apr-2021 | $353K | $763K | Completed | Generating Revenue | |
| 1. Seed Round | 19-Jun-2020 | $410K | $410K | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
CUePEAK Bio Patents
CUePEAK Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4837576-A1 | Composition comprising tubulin inhibitor for preventing or treating skin diseases | Pending | 06-Jan-2025 | ||
| EP-4837581-A1 | Composition comprising tubulin inhibitor for preventing or treating skin diseases | Pending | 06-Jan-2025 | ||
| WO-2025147178-A1 | Composition comprising tubulin inhibitor for preventing or treating skin diseases | Inactive | 05-Jan-2024 | ||
| WO-2025147180-A1 | Composition comprising tubulin inhibitor for preventing or treating skin diseases | Inactive | 05-Jan-2024 | ||
| WO-2025147181-A1 | Composition for preventing or treating hair loss comprising tubulin inhibitor | Inactive | 05-Jan-2024 | A61K31/44 |
CUePEAK Bio Signals
CUePEAK Bio Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Rising S Ventures | Venture Capital | Minority | ||
| Bluepoint | Venture Capital | Minority | ||
| Capstone Partners | Investment Bank | Minority | ||
| Capstone Partners Korea | Venture Capital | Minority | ||
| Korea Technology Finance | Government | Minority |
CUePEAK Bio FAQs
-
When was CUePEAK Bio founded?
CUePEAK Bio was founded in 2020.
-
Where is CUePEAK Bio headquartered?
CUePEAK Bio is headquartered in Daejeon, South Korea.
-
What is the size of CUePEAK Bio?
CUePEAK Bio has 4 total employees.
-
What industry is CUePEAK Bio in?
CUePEAK Bio’s primary industry is Drug Discovery.
-
Is CUePEAK Bio a private or public company?
CUePEAK Bio is a Private company.
-
What is CUePEAK Bio’s current revenue?
The current revenue for CUePEAK Bio is .
-
How much funding has CUePEAK Bio raised over time?
CUePEAK Bio has raised $763K.
-
Who are CUePEAK Bio’s investors?
Rising S Ventures, Bluepoint, Capstone Partners, Capstone Partners Korea, and Korea Technology Finance are 5 of 8 investors who have invested in CUePEAK Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process